NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

NCT07041606

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Endometrial Cancer

Countries: Russia

Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Female patients aged ≥ 18 years old;
2. Signed ICF, including consent for archival FFPE tumor tissue block testing;
3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
5. The presence of biopsy or postoperative archival FFPE tumor sample (block);
6. Availability of source medical documentation.

Exclusion Criteria:

1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.

Locations (19)

Arkhangelsk, Russia
Barnaul, Russia
Chelyabinsk, Russia
Irkutsk, Russia
Izhevsk, Russia
Krasnodar, Russia
Krasnoyarsk, Russia
Moscow, Russia
Murmansk, Russia
Obninsk, Russia
Saint Petersburg, Russia
Severodvinsk, Russia
Sochi, Russia
Tomsk, Russia
Tver', Russia
Ufa, Russia
Vladivostok, Russia
Yaroslavl, Russia
Yekaterinburg, Russia